Metformin: What's new in the changing world of type 2 diabetes?
You need to login to participate in this education.
This education is accredited: RACGP 2 CPD, ACRRM 1.00 CME PD.
Metformin is an integral part of glycaemic management in T2D, and is recommended as first-line therapy in Australian and international guidelines. This module outlines the person-centred use of metformin in primary care using a case study approach, and explores considerations around the use of pharmacotherapy in T2D patients with renal impairment.
By completing this learning activity, participants will be able to:
- Discuss the history of metformin as a glucose-lowering medication and understand why it is recommended as initial pharmacotherapy for type 2 diabetes (T2D) by major Australian and international guidelines.
- Describe the clinical benefits of metformin beyond its glucose-lowering effects.
- Explain latest recommendations around the use of metformin in people with type 2 diabetes and chronic kidney disease (CKD).
- Understand how metformin can be combined with second-line agents in the treatment of type 2 diabetes in patients with CKD.
This activity is ADEA endorsed for 1 CPD point. Endorsement ends December 2022.
This activity is sponsored by Boehringer Ingelheim.
|Metformin: What's new in the changing world of type 2 diabetes? - Education|
|Metformin: What's new in the changing world of type 2 diabetes? - Evaluation|